What did @daniconwayofficial actually say?
The creator laid out three delivery options for BPC-157: injectable, oral, and nasal. Her core argument is that injectable is "the best option for systemic improvement" regardless of the goal, because it bypasses gut absorption entirely. She credited oral forms with being useful specifically for gut health, since the peptide contacts gut tissue directly. On nasal delivery, she was dismissive: "not BPC" was essentially the verdict.
She also tied this to a practical point that resonates with a lot of the functional medicine crowd. People chasing BPC-157 for gut issues often have compromised absorption to begin with, so relying on their gut to absorb the thing meant to fix their gut is, as she implies, a bit circular. That logic is worth taking seriously.
Does the science back this up?
Partially, but the picture is more complicated than a clean injectable-wins ranking suggests. Most of the evidence base for BPC-157 is preclinical. We're talking rat and rodent models, not randomized controlled trials in humans. That context matters enormously when making route-of-administration claims.
In animal studies, both systemic (injected) and intragastric (oral) administration of BPC-157 have shown effects on gut mucosa repair, tendon healing, and angiogenesis. Sikiric et al. (2018, Current Pharmaceutical Design) documented effects via both routes in rodent models of gut injury. The oral route produced measurable systemic effects in some studies, not just local gut effects, which complicates the creator's framing that oral is mainly a gut-only tool.
On the other hand, bioavailability data for oral peptides in humans is genuinely weak. Peptides are vulnerable to proteolytic degradation in the GI tract. The argument that injectable bypasses this problem is pharmacologically sound. But "pharmacologically sound argument" and "proven in human clinical trials" are not the same thing.
What did they get right (or wrong)?
Credit where it's due: the basic pharmacology argument for injectable being more reliably absorbed is reasonable. Peptides face real degradation challenges in the GI tract, and for someone with gut dysbiosis or permeability issues, oral absorption is genuinely unpredictable. That's not wrong.
Where the framing gets sloppy is the confident hierarchy she builds around human outcomes. Saying injectable is "going to be the best with whatever you're looking to get results for" implies comparative clinical data that doesn't exist yet for humans. We don't have head-to-head human trials comparing injectable versus oral BPC-157 for joint recovery, systemic inflammation, or gut repair.
The nasal dismissal is also worth questioning. While intranasal BPC-157 research is thin, there are peptides like Semax and Selank where intranasal delivery is well-documented for CNS access. She's right that BPC-157 isn't one of the better-studied intranasal options, but framing it as nearly useless intranasally without citing why is an assertion, not an evidence-based conclusion.
What should you actually know?
BPC-157 remains an unscheduled, research-stage peptide. It is not FDA-approved for any indication. Every claim about optimal dosing routes, including this one, is being made in a near-vacuum of human clinical trial data. Animal models are promising but they have a long history of not translating cleanly to human medicine.
If you're considering BPC-157, the route-of-administration question is genuinely relevant, and talking to a licensed provider who understands peptide pharmacology matters more than Instagram consensus. The creator's general logic around absorption and compromised gut function isn't baseless, but it is being stated with more certainty than the evidence supports.
Also worth noting: "systemic improvement" is doing a lot of work in this video. Joint healing, gut repair, and neurological recovery involve different mechanisms, different tissue targets, and different evidence bases. Collapsing them under one route recommendation oversimplifies a genuinely complex pharmacology question.